Bulletin from the Annual General Meeting of Dignitana AB (publ)
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Dignitana AB (publ) (“Dignitana” or the “Company”) on 20 May 2021. Due to the covid-19 pandemic, Dignitana’s Annual General Meeting was carried out through advance voting (postal voting) only.
Adoption of income statement and balance sheet and discharge from liability
The AGM resolved to adopt the income statement for the financial year 2020 as well as the balance sheet and consolidated balance sheet as of 31 December 2020. The members of the board of directors and the managing director were discharged from liability for the financial year 2020.
Allocation of profit or loss
The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2020 and that the results of the Company shall be carried forward.
Board of Directors and auditor
The AGM resolved, in accordance with the nomination committee’s proposal, on re-election of
Klas Arildsson, William Cronin, Richard DiIorio, Christian Lindgren and Ljubo Mrnjavac and election of Lina Karlsson as board members. Klas Arildsson was re-elected as the chairman of the Board of Directors. The AGM re-elected the audit firm Öhrlings PricewaterhouseCoopers AB as auditor.
The AGM further resolved on remuneration to the Board of Directors in accordance with the nomination committee’s proposal. The AGM furthermore resolved in accordance with the nomination committee’s proposal, that remuneration to the auditor shall be paid in accordance with approved invoicing.
Nomination committee for the next annual general meeting
The AGM resolved, in accordance with the nomination committee’s proposal, on principles for appointing the nomination committee.
Amendment of the articles of association
The AGM resolved, in accordance with the Board of Directors’ proposal, to amend the articles of association. The amendment was made in order to comply with new rules.
Authorization to issue new shares, warrants or convertibles
The AGM resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, at one or several occasions and for the period up until the next annual general meeting, resolve to increase the Company’s share capital by issuing new shares, warrants or convertibles. Such issue resolution may be carried out with or without deviation from the shareholders’ pre-emption rights and with or without provisions for contribution in kind, set-off or other conditions. The total number of shares that may be issued, or in the event of an issue of warrants or convertibles, any additional shares after conversion or exercise of any warrant, pursuant to the authorization and with deviation from the shareholders' pre-emption rights shall be limited to 10 percent of the outstanding shares as per this day. Such an issue, shall be carried out with a view to broadening the ownership, procuring or facilitating the procurement of working capital and/or making acquisitions, or procuring or facilitating the procurement of capital for acquisitions.
For More Information Contact
Melissa Bourestom, VP Corporate Communications, email@example.com +1 469-518-5031
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, firstname.lastname@example.org. Learn more at www.dignitana.se or www.dignicap.com.